Canadian Agency for Drugs and Technologies in Health. (2019). Clinical review report: Rivaroxaban (Xarelto) Bayer Inc: Indication : in combination with 75 mg to 100 mg acetylsalicylic acid, for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease with or without peripheral artery disease (Final (with redactions).). Ottawa (ON): CADTH.
Chicago Style CitationCanadian Agency for Drugs and Technologies in Health. Clinical Review Report: Rivaroxaban (Xarelto) Bayer Inc: Indication : In Combination With 75 Mg to 100 Mg Acetylsalicylic Acid, for the Prevention of Stroke, Myocardial Infarction, and Cardiovascular Death, and for the Prevention of Acute Limb Ischemia and Mortality in Patients With Coronary Artery Disease With or Without Peripheral Artery Disease. Final (with redactions). Ottawa (ON): CADTH, 2019.
MLA CitationCanadian Agency for Drugs and Technologies in Health. Clinical Review Report: Rivaroxaban (Xarelto) Bayer Inc: Indication : In Combination With 75 Mg to 100 Mg Acetylsalicylic Acid, for the Prevention of Stroke, Myocardial Infarction, and Cardiovascular Death, and for the Prevention of Acute Limb Ischemia and Mortality in Patients With Coronary Artery Disease With or Without Peripheral Artery Disease. Final (with redactions). Ottawa (ON): CADTH, 2019.